[go: up one dir, main page]

WO2001030331A3 - Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c - Google Patents

Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c Download PDF

Info

Publication number
WO2001030331A3
WO2001030331A3 PCT/US2000/026254 US0026254W WO0130331A3 WO 2001030331 A3 WO2001030331 A3 WO 2001030331A3 US 0026254 W US0026254 W US 0026254W WO 0130331 A3 WO0130331 A3 WO 0130331A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
protein kinase
therapeutic compositions
compositions including
including protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/026254
Other languages
English (en)
Other versions
WO2001030331A2 (fr
Inventor
Norman Eugene Cameron
Douglas Kirk Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU11892/01A priority Critical patent/AU1189201A/en
Publication of WO2001030331A2 publication Critical patent/WO2001030331A2/fr
Publication of WO2001030331A3 publication Critical patent/WO2001030331A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions comprenant un inhibiteur de la protéine kinase C (PKC), ou un sel de celui-ci acceptable d'un point de vue pharmaceutique, et un acide gras essentiel antioxydant, ou un agent de prostacycline, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique. L'invention concerne également des méthodes de traitement consistant à administrer ces compositions, et des méthodes de traitement consistant à co-administrer un inhibiteur de la PKC, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique, et un acide gras essentiel antioxydant, ou un agent de prostacycline, ou un sel de celui-ci acceptable d'un point de vue pharmaceutique.
PCT/US2000/026254 1999-10-22 2000-10-13 Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c Ceased WO2001030331A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11892/01A AU1189201A (en) 1999-10-22 2000-10-13 Therapeutic compositions including protein kinase c inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16112999P 1999-10-22 1999-10-22
US60/161,129 1999-10-22
US17751000P 2000-01-21 2000-01-21
US60/177,510 2000-01-21

Publications (2)

Publication Number Publication Date
WO2001030331A2 WO2001030331A2 (fr) 2001-05-03
WO2001030331A3 true WO2001030331A3 (fr) 2002-01-24

Family

ID=26857534

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026254 Ceased WO2001030331A2 (fr) 1999-10-22 2000-10-13 Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c

Country Status (2)

Country Link
AU (1) AU1189201A (fr)
WO (1) WO2001030331A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002116A2 (fr) * 2000-06-29 2002-01-10 Eli Lilly And Company Traitement therapeutique du cancer au moyen d'un inhibiteur de la proteine kinase c
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
CA2393720C (fr) 2002-07-12 2010-09-14 Eli Lilly And Company Monochlorhydrate de 3-(1-methyl-1h-indol-3-yl)-4-[[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole-2,5-dione cristallin
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
JP4157889B2 (ja) * 2003-06-25 2008-10-01 有限会社 循環器研究所 性交機能改善用外用製剤
ES2307059T3 (es) * 2003-10-24 2008-11-16 Eli Lilly And Company Bisindolilmaleimidas utiles para tratar el cancer de prostata y enfermedades mediadas por akt.
WO2006019851A1 (fr) * 2004-07-23 2006-02-23 Eli Lilly And Company Procédé pour diagnostiquer ou traiter des complications microvasculaires diabétiques
EP1621201A1 (fr) * 2004-07-28 2006-02-01 NeuroCode AG Hesperidin pour la prophylaxe et le traitement de maladies du système nerveux central, en particulier la maladie d'Alzheimer et de Parkinson, pour thérapie après accident ischémique cérébral et de la douleur chronique.
DE502005002104D1 (de) * 2005-05-13 2008-01-10 Mewicon Med Wiss Beratung Gmbh Hesperidin zur Behandlung von Epilepsie
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
KR102069912B1 (ko) 2012-03-16 2020-01-23 비타이 파마슈티컬즈, 엘엘씨 간 x 수용체 조절제
NZ629189A (en) 2012-03-16 2016-08-26 Vitae Pharmaceuticals Inc Liver x receptor modulators
WO2016003450A1 (fr) 2014-07-01 2016-01-07 The Regents Of The University Of California Inhibiteurs de pkc-epsilon
RU2742030C1 (ru) * 2020-06-11 2021-02-01 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Конъюгат гесперидина и способ его получения

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K.HEHENBERGER, A.HANSSON: "High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors", CELL BIOCHEMISTRY AND FUNCTION, vol. 15, no. 3, 1997, pages 197 - 201, XP001010004 *
S.E.BURSELL, G.L.KING: "Can protein kinase C inhibition", DIABETES RESEARCH CLINICAL PRACTICE, vol. 45, no. 2-3, 1999, pages 169 - 182, XP001010001 *

Also Published As

Publication number Publication date
WO2001030331A2 (fr) 2001-05-03
AU1189201A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
WO2003000343A3 (fr) Administration d'inhibiteurs de phosphodiesterase destinee au traitement de l'ejaculation precoce
WO2001019829A3 (fr) Pyrazolopyrimidines en tant qu'agents therapeutiques
WO2003000695A8 (fr) Pyrrolopyrimidines utilisees en tant qu'inhibiteurs des proteines kinases
WO2001030331A3 (fr) Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c
WO2005005414A3 (fr) Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
MY129350A (en) Aripiprazole oral solution
CA2363990A1 (fr) Utilisation de glycyrrhizine pour traiter une mastite
AU7031500A (en) Therapeutic quinazoline compounds
CA2426703A1 (fr) Agents therapeutiques et procede d'utilisation de ces derniers pour modules l'angiogenese
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
AU3850600A (en) Dalda analogs and their use
WO2005014572A8 (fr) Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases
WO2000045800A3 (fr) Effets immunosuppresseurs des derives de pteridine
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2003048122A3 (fr) Inhibiteurs de phospholipase a2 cytosolique
WO2002007721A3 (fr) Methode
EP1886691A3 (fr) Formulation pharmaceutique comprenant un inhibiteur de la thrombine à faible masse moléculaire et son précurseur
WO2003005967A3 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
WO2002102743A3 (fr) Aminoalkylesters d'acide diphenylalcoxy-acetique n et alpha-substitues deuterises et medicaments contenant lesdits composes
CA2389032A1 (fr) Agents de prevention ou de traitement de maladies inflammatoires de l'intestin
WO2000001415A3 (fr) Utilisation d'inhibiteurs de la proteine kinase c epsilon dans le traitement de la douleur
WO2003051838A3 (fr) Inhibiteurs de la proteine kinase
AU7270798A (en) Antithrombotic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP